DK173283B1 - Krystallinsk, vandfri o-form af 2-[4-(2-furoyl)-piperazin-1-yl]-4-amino-6,7-dimethoxyquinazolinhydrochlorid samt lægemiddel - Google Patents

Krystallinsk, vandfri o-form af 2-[4-(2-furoyl)-piperazin-1-yl]-4-amino-6,7-dimethoxyquinazolinhydrochlorid samt lægemiddel Download PDF

Info

Publication number
DK173283B1
DK173283B1 DK198701398A DK139887A DK173283B1 DK 173283 B1 DK173283 B1 DK 173283B1 DK 198701398 A DK198701398 A DK 198701398A DK 139887 A DK139887 A DK 139887A DK 173283 B1 DK173283 B1 DK 173283B1
Authority
DK
Denmark
Prior art keywords
hydrochloride
amino
piperazin
furoyl
prazosin
Prior art date
Application number
DK198701398A
Other languages
Danish (da)
English (en)
Other versions
DK139887A (da
DK139887D0 (da
Inventor
Helmut Schickaneder
Ingomar Grafe
Kurt Henning Ahrens
Original Assignee
Heumann Pharma Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heumann Pharma Gmbh & Co filed Critical Heumann Pharma Gmbh & Co
Publication of DK139887D0 publication Critical patent/DK139887D0/da
Publication of DK139887A publication Critical patent/DK139887A/da
Application granted granted Critical
Publication of DK173283B1 publication Critical patent/DK173283B1/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK198701398A 1986-03-21 1987-03-18 Krystallinsk, vandfri o-form af 2-[4-(2-furoyl)-piperazin-1-yl]-4-amino-6,7-dimethoxyquinazolinhydrochlorid samt lægemiddel DK173283B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP86103925A EP0237608B1 (de) 1986-03-21 1986-03-21 Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
EP86103925 1986-03-21

Publications (3)

Publication Number Publication Date
DK139887D0 DK139887D0 (da) 1987-03-18
DK139887A DK139887A (da) 1987-09-22
DK173283B1 true DK173283B1 (da) 2000-06-13

Family

ID=8194990

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198701398A DK173283B1 (da) 1986-03-21 1987-03-18 Krystallinsk, vandfri o-form af 2-[4-(2-furoyl)-piperazin-1-yl]-4-amino-6,7-dimethoxyquinazolinhydrochlorid samt lægemiddel

Country Status (19)

Country Link
US (1) US4816455B1 (xx)
EP (1) EP0237608B1 (xx)
JP (1) JPH0662615B2 (xx)
KR (1) KR870008875A (xx)
AR (1) AR242384A1 (xx)
AT (1) ATE72244T1 (xx)
AU (1) AU586318B2 (xx)
CA (1) CA1240999A (xx)
DE (1) DE3683760D1 (xx)
DK (1) DK173283B1 (xx)
ES (1) ES2009486A6 (xx)
GR (1) GR870429B (xx)
HU (1) HU200176B (xx)
ID (1) ID810B (xx)
IE (1) IE59913B1 (xx)
IL (1) IL81841A (xx)
NZ (1) NZ219644A (xx)
PT (1) PT84496B (xx)
ZA (1) ZA87966B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
EP0794178A4 (en) * 1994-11-25 1998-02-25 Nippon Chemiphar Co CHINAZOLIN DERIVATIVES
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
PT849266E (pt) * 1996-12-20 2007-03-30 Heumann Pcs Gmbh Nova forma polimorfa de mesilato de doxazosina (forma iii)
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
TR200000458T1 (tr) 1998-06-19 2000-10-23 Teijin Limited 2-(3-siyano-4-izobütiloksifenil)-4-Metil-5-tiazolkarboksilik asit ve bunun üretilmesi için yöntem.
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1826207A4 (en) * 2004-11-12 2009-05-20 Teijin Pharma Ltd ACID SALT OF A BENZIMIDAZOLE DERIVATIVE AND CRYSTAL THEREOF
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0917675A2 (pt) * 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
ATE32074T1 (de) * 1983-11-22 1988-02-15 Heumann Ludwig & Co Gmbh Verfahren zur herstellung von 4-amino-6,7dimethoxy-2-(4-(furo-2-yl)-piperazin-1-yl)chinazolin und dessen physiologisch annehmbarer salze.
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.

Also Published As

Publication number Publication date
EP0237608A1 (de) 1987-09-23
GR870429B (en) 1987-07-13
HU200176B (en) 1990-04-28
IE870705L (en) 1987-09-21
AR242384A1 (es) 1993-03-31
DK139887A (da) 1987-09-22
PT84496A (de) 1987-04-01
PT84496B (pt) 1989-11-10
AU586318B2 (en) 1989-07-06
IE59913B1 (en) 1994-04-20
ATE72244T1 (de) 1992-02-15
NZ219644A (en) 1989-04-26
ES2009486A6 (es) 1989-10-01
DE3683760D1 (de) 1992-03-12
EP0237608B1 (de) 1992-01-29
US4816455B1 (en) 1992-11-24
IL81841A0 (en) 1987-10-20
IL81841A (en) 1991-06-10
KR870008875A (ko) 1987-10-21
HUT47101A (en) 1989-01-30
US4816455A (en) 1989-03-28
ID810B (id) 1996-07-15
ZA87966B (en) 1987-08-04
AU6870787A (en) 1987-09-24
CA1240999A (en) 1988-08-23
JPS62226980A (ja) 1987-10-05
DK139887D0 (da) 1987-03-18
JPH0662615B2 (ja) 1994-08-17

Similar Documents

Publication Publication Date Title
DK173283B1 (da) Krystallinsk, vandfri o-form af 2-[4-(2-furoyl)-piperazin-1-yl]-4-amino-6,7-dimethoxyquinazolinhydrochlorid samt lægemiddel
US4739055A (en) Anhydrous, stable, crystalline δ-form of prazosin hydrochloride
NO148583B (no) Kohesive, bare til seg selv og ikke til fremmedlegemer klebende bind for fremstilling av fikseringsbandasjer, og fremgangsmaate til fremstilling av slike bind
EP2262771A1 (en) A method for the preparation of dabigatran
BROWN et al. Structure and antimicrobial activity of the 3-aminorhodanines
JP2022000462A (ja) エパルレスタットを調製する方法
SU677655A3 (ru) Способ получени -циклоалкилметил-2-фениламиноимидазолинов-2или их солей
EP2483256A1 (en) Processes for preparing febuxostat
FI87768B (fi) Foerfarande foer framstaellning av 1,6-di(n3-cyan-n1-guanidino)hexan
RU2308448C1 (ru) Способ получения этилендиамин-n, n, n`, n`-тетрапропионовой кислоты
KR20080019151A (ko) 카르보스티릴 화합물의 제조 방법
RU2397978C2 (ru) 1-[2-(4-бензил-4-гидроксипиперидин-1-ил)-этил]-3-(2-метилхинолин-4-ил)-мочевина в виде кристаллического сульфата
JPH0541631B2 (xx)
CN102336701A (zh) 硫酸卡维地洛的结晶、其制备方法及其在医药上的应用
JP2007538087A (ja) 結晶固形ファムシクロビルを調製するための乾燥方法
KR20030014403A (ko) N-[4-(3-클로로-4-플루오로페닐아미노)-7-(3-모르폴린-4-일프로폭시)-퀴나졸린-6-일]-아크릴아미드디하이드로클로라이드의 다형체/수화물
DK157548B (da) Fremgangsmaade til fremstilling af den krystallinske alfa-form af hydrochloridet af prazosinchlorid
RU2404977C1 (ru) Способ получения и очистки n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5-пиримидинсульфон)-n'-изоникотиноилгидразида
RU2131875C1 (ru) Способ получения высокочистого буспирона и его хлоргидратов
JPH0570461A (ja) イソキノリン化合物の製造法
Baxter et al. 74. Pyrazine derivatives. Part I. 2-Hydroxy-3: 6-dimethylpyrazine
JPH0428264B2 (xx)
JPS6125713B2 (xx)
DE2129236A1 (de) Neue Sulfonylsemicarbazide und Verfah ren zu deren Herstellung sowie ihre Ver Wendung als Arzneimittel
MX2015006519A (es) Metodo para preparar derivados de feniloximetil-nitro-imidazol y uso del mismo.

Legal Events

Date Code Title Description
PUP Patent expired